tamoxifen
Extended use of breast cancer drug tamoxifen linked to increased endometrial cancer risk
July 9, 2018Research and Development, Sales and Marketing Cancer, breast cancer, endometrial cancer, pharma, tamoxifen
New evidence published in the British Journal of Surgery has indicated a troubling link between long-term use of the breast …
Breast cancer recurrence can occur up to 20 years after treatment, report shows
November 10, 2017Medical Communications, Research and Development Cancer, breast cancer, pharma, tamoxifen
New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …
Tamoxifen found to reduce breast cancer rates by 30%
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arimidex, NICE, anastrozole, astrazenea, breast cancer, tamoxifen
A study from Queen Mary University has demonstrated that tamoxifen can reduce breast cancer rates by around 30% over 20 …
NICE finalises tamoxifen guidance
June 26, 2013Sales and Marketing Evista, NICE, lilly, tamoxifen
Women at risk of breast cancer can now be offered a daily pill on the NHS to stop the disease …
NICE consults on tamoxifen
January 15, 2013Sales and Marketing Cancer, Evista, NICE, lilly, tamoxifen
Patient groups have welcomed NICE’s new draft guideline recommending the use of preventive treatments in women who have a family …
Hormone therapy drugs ‘increase heart disease risk’
December 10, 2010Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen
Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …
Latest content
FibroFind appoints Lee Borthwick as CEO
